BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 16842143)

  • 1. Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions.
    Lonn E; Grewal J
    Curr Vasc Pharmacol; 2006 Jul; 4(3):253-68. PubMed ID: 16842143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.
    Yusuf S; Islam S; Chow CK; Rangarajan S; Dagenais G; Diaz R; Gupta R; Kelishadi R; Iqbal R; Avezum A; Kruger A; Kutty R; Lanas F; Lisheng L; Wei L; Lopez-Jaramillo P; Oguz A; Rahman O; Swidan H; Yusoff K; Zatonski W; Rosengren A; Teo KK;
    Lancet; 2011 Oct; 378(9798):1231-43. PubMed ID: 21872920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
    Ferdinand KC
    J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
    ; Yusuf S; Pais P; Afzal R; Xavier D; Teo K; Eikelboom J; Sigamani A; Mohan V; Gupta R; Thomas N
    Lancet; 2009 Apr; 373(9672):1341-51. PubMed ID: 19339045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Secondary Prevention (MISSION-1) Study.
    Rao C; Du J; Li X; Li J; Zhang H; Zhao Y; Hu S; Jiang L; Zheng Z;
    Am Heart J; 2016 Aug; 178():9-18. PubMed ID: 27502847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill.
    González-Juanatey JR; Mostaza JM; Lobos JM; Abarca B; Llisterri JL
    Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):547-50. PubMed ID: 27062678
    [No Abstract]   [Full Text] [Related]  

  • 9. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.
    Barry AR; Koshman SL; Norris CM; Ross DB; Pearson GJ
    Pharmacotherapy; 2014 May; 34(5):464-72. PubMed ID: 24877186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute ischemic coronary artery disease and ischemic stroke: similarities and differences.
    Fisher M; Folland E
    Am J Ther; 2008; 15(2):137-49. PubMed ID: 18356634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Use for Secondary Prevention of Cardiovascular Diseases in Golestan, Iran: Results From the Golestan Cohort Study.
    Nalini M; Sepanlou SG; Pourshams A; Poustchi H; Sharafkhah M; Bahrami H; Kamangar F; Malekzadeh R
    Arch Iran Med; 2018 Mar; 21(3):86-94. PubMed ID: 29688733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables.
    Feher G; Koltai K; Papp E; Alkonyi B; Solyom A; Kenyeres P; Kesmarky G; Czopf L; Toth K
    Drugs Aging; 2006; 23(7):559-67. PubMed ID: 16930084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Missed opportunities for the secondary prevention of cardiovascular disease in Canada.
    Hackam DG; Leiter LA; Yan AT; Yan RT; Mendelsohn A; Tan M; Zavodni L; Chen R; Tsang JL; Kundi A; Lin PJ; Fitchett DH; Langer A; Goodman SG;
    Can J Cardiol; 2007 Dec; 23(14):1124-30. PubMed ID: 18060097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Secondary medical prevention in patients with peripheral arterial disease.
    Schouten O; Welten GM; Bax JJ; Poldermans D
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):59-60. PubMed ID: 17719805
    [No Abstract]   [Full Text] [Related]  

  • 16. [Changes in the prescription of cardiovascular prevention drugs in France between 1995 and 2003: factors influencing the gap between evidence base medicine and clinical practice].
    Philippe F; Cambou JP; Danchin N; Thomas D
    Ann Cardiol Angeiol (Paris); 2005 Dec; 54 Suppl 1():S30-6. PubMed ID: 16411649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology.
    Gyberg V; De Bacquer D; De Backer G; Jennings C; Kotseva K; Mellbin L; Schnell O; Tuomilehto J; Wood D; Rydén L; Amouyel P; Bruthans J; Conde AC; Cifkova R; Deckers JW; De Sutter J; Dilic M; Dolzhenko M; Erglis A; Fras Z; Gaita D; Gotcheva N; Goudevenos J; Heuschmann P; Laucevicius A; Lehto S; Lovic D; Miličić D; Moore D; Nicolaides E; Oganov R; Pająk A; Pogosova N; Reiner Z; Stagmo M; Störk S; Tokgözoğlu L; Vulic D;
    Cardiovasc Diabetol; 2015 Oct; 14():133. PubMed ID: 26427624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
    Makam RC; Erskine N; McManus DD; Lessard D; Gore JM; Yarzebski J; Goldberg RJ
    Am J Cardiol; 2016 Dec; 118(12):1792-1797. PubMed ID: 27743577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. President's page: the promise of prevention: so, why aren't all cardiologists "preventive"?
    Wolk MJ; Bairey Merz CN; Thompson PD
    J Am Coll Cardiol; 2004 Nov; 44(10):2082-4. PubMed ID: 15542296
    [No Abstract]   [Full Text] [Related]  

  • 20. Implementing guidelines in primary care: can population impact measures help?
    Heller RF; Edwards R; McElduff P
    BMC Public Health; 2003 Jan; 3():7. PubMed ID: 12542840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.